Table 6: Risk of arterial/venous thromboembolism with AI's and recommendations.

Drug name Risk of ATE Risk of VTE Recommendations
Axitinib ✓ ✓ Axitinib should be used with caution in patients who are at increased
risk of thromboembolic events as well as in patients who have a prior
history of these events [24].
Bevacizumab ✓ ✓

Bevacizumab should be discontinued in all patients who experience a
severe ATE and safety of its resumption has not been studied yet.

Permanently discontinue Bevacizumab therapy in patients with life-threatening
(grade 4) VTE`s [28].
Cabozantinib ✓ ✓ Should be discontinued in patients who experience acute MI as well as
in patients who develop any other clinically significant arterial
thrombotic complications [29].
Erlotinib ✓ ✓ No specific recommendations [30].
Nilotinib ✓ Not reported

Patients who are being started on Nilotinib should be advised to seek
immediate medical attention, should they develop any signs or
symptoms of cardiovascular events.

Before starting Nilotinib, patients cardiovascular status should be
evaluated and cardiovascular risk factors should be monitored and
managed regularly according to the standard guidelines [31].
Panitumumab Not reported ✓ No specific recommendations [32].
Pazopanib ✓ ✓ Pazopanib should be used with caution in patients with a history of
ATE`s or who are at increased risk of ATE`s. All patients should be
monitored for signs and symptoms VTE and PE during Pazopanib
therapy [33].
Ponatinib ✓ ✓ In patients suspected of developing ATE`s, it is recommended that the
treatment should be discontinued and a benefit-risk re-consideration
should guide the decision to restart the therapy with Ponatinib. In
patients who develop serious VTE, dose modification or discontinuation
of the drug should be considered [34].
Ramucirumab ✓ Not reported It should be permanently discontinued in patients experiencing a severe
ATE [35].
Regorafenib ✓ Not reported It should be discontinued in patients who develop new or acute onset
myocardial ischemia or infarction. Resumption of the treatment should
be based upon consideration of potential benefits versus risks of further
cardiac ischemia [36].
Sorafenib ✓ Not reported Temporary or permanent discontinuation of sorafenib should be
considered in case of development of cardiac ischemia or infarction in a
patient [37].
Vandetanib ✓ Not reported Vandetanib should be discontinued in patients who experience severe
thrombotic events [38].
Ziv-Aflibercept ✓ Not reported Ziv-aflibercept should be discontinued in patients experiencing an ATE
[39].

✓: Yes.